Aripiprazole

證據等級: L5

預測適應症: 5 個

Aripiprazole: From Schizophrenia / Bipolar Disorder to Autism Spectrum Disorder

One-Sentence Summary

Aripiprazole is a third-generation atypical antipsychotic with a unique “dopamine system stabilizer” profile (D2/D3 partial agonist, 5-HT1A partial agonist, 5-HT2A antagonist), established globally for schizophrenia and bipolar disorder. The TxGNN model’s top actionable prediction is Autism (irritability associated with autism spectrum disorder), backed by multiple completed Phase 3 double-blind RCTs and 20+ publications, including FDA approval for this indication in children aged 6–17. Note: The highest-ranked model output was “autism susceptibility 1” (a genetic susceptibility locus), for which no clinical evidence exists and a Hold decision applies; the clinically actionable prediction is autism proper (Rank 2, Evidence Level L1).

Quick Overview

Item	Content
Original Indication	Schizophrenia, Bipolar Disorder (established global approvals; Malaysia-specific indication text unavailable in current dataset)
Predicted New Indication	Autism (Irritability Associated with Autism Spectrum Disorder)
TxGNN Prediction Score	N/A (score field returned 0.00% — likely not computed in this model run)
Evidence Level	L1 (≥2 completed Phase 3 RCTs)
Malaysia Market Status	✓ Marketed
Number of Registrations	26
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Aripiprazole functions as a dopamine system stabilizer through its partial agonism at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, combined with antagonism at 5-HT2A receptors. In brain regions where dopamine is pathologically elevated (e.g., the mesolimbic system during agitation or aggression), aripiprazole acts as a functional brake; in regions with insufficient dopaminergic tone (e.g., the prefrontal cortex), it provides partial support. Crucially, this mechanism is distinct from full D2 blockade: aripiprazole carries a markedly lower burden of extrapyramidal symptoms, metabolic disturbance, and sedation — properties that make it particularly suitable for long-term use in pediatric populations.

In autism spectrum disorder (ASD), the behavioral symptoms most disruptive to daily functioning — including irritability, explosive aggression, self-injurious behavior, and severe tantrums — are linked to dysregulation of dopaminergic and serotonergic circuits. The 5-HT1A partial agonist component of aripiprazole provides anxiolytic effects that may help stabilize emotional dysregulation; D2/D3 partial agonism blunts dopamine-driven impulsivity. Animal models have additionally shown that dopamine-stabilizing agents can improve repetitive behavior patterns and social behavioral deficits relevant to ASD.

This prediction is not speculative: aripiprazole received FDA approval in 2009 specifically for irritability associated with autistic disorder in children and adolescents aged 6–17 years, based on pivotal multicenter Phase 3 RCTs. The transition from a schizophrenia/bipolar disorder drug to ASD behavioral management is mechanistically coherent and clinically validated, making it one of the best-supported drug repurposing stories in pediatric psychiatry. The key clinical question for Malaysia is therefore not whether the evidence is sufficient, but whether this specific indication is currently registered among the 26 existing product licenses.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00332241	Phase 3	Completed	98	Multicenter double-blind RCT: aripiprazole flexible dose vs. placebo in children and adolescents with autistic disorder — one of the two FDA pivotal trials underpinning the 2009 approval for ASD irritability
NCT00337571	Phase 3	Completed	218	Multicenter double-blind RCT: three fixed doses of aripiprazole (5/10/15 mg) vs. placebo in children and adolescents with autistic disorder — the companion FDA pivotal trial
NCT00198107	Phase 3	Completed	81	Assessed aripiprazole and D-cycloserine in autism in children; directly evaluated aripiprazole as monotherapy for ASD-associated symptoms, considered a foundational approval-support trial
NCT01227668	Phase 4	Completed	215	Long-term maintenance RCT: patients stabilized on aripiprazole were randomized to continue or switch to placebo; assessed time to relapse of irritability in pediatric autistic disorder
NCT00365859	Phase 3	Completed	330	52-week multicenter open-label extension providing long-term safety and tolerability data for aripiprazole in children and adolescents with autistic disorder; largest long-term safety dataset for this population
NCT03487770	Phase 3	Completed	111	Multicenter double-blind RCT: aripiprazole oral solution (2–15 mg) vs. placebo over 8 weeks in children and adolescents with autistic disorder; assessed steady-state pharmacokinetics alongside efficacy
NCT01617447	Phase 3	Completed	92	Short-term (8-week) oral aripiprazole efficacy and safety study in pediatric autistic disorder in Japan; provides Asia-specific clinical data
NCT01617460	Phase 3	Completed	86	Long-term safety and efficacy extension of the short-term Japan study (NCT01617447) in pediatric autistic disorder; supports sustained use data in Asian populations
NCT03179787	Phase N/A	Completed	528	Post-marketing surveillance study in Japan evaluating real-world safety and effectiveness of aripiprazole in autism patients; the largest real-world dataset from an Asian market
NCT01028820	Phase 4	Completed	13	8-week fMRI neuroimaging study exploring brain activation patterns during aripiprazole treatment in ASD; provides mechanistic imaging evidence supporting the D2/serotonin pathway hypothesis

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35101925	2023	Overview of Systematic Reviews	BMJ Evidence-Based Medicine	Synthesized multiple systematic reviews on risperidone and aripiprazole for children with ASD; aripiprazole showed significant, clinically meaningful reduction in irritability with a more favorable metabolic profile than risperidone
35470032	2023	Systematic Review + Meta-analysis	JAACAP	First meta-analysis assessing a broad range of pharmacological interventions for emotional dysregulation and irritability in ASD; aripiprazole demonstrated statistically significant superiority over placebo in reducing irritability subscale scores
38263251	2024	Systematic Review + Network Meta-analysis	Molecular Autism	Comprehensive NMA of pharmacological and non-pharmacological interventions for ASD irritability with GRADE assessment; aripiprazole ranked as one of the most effective pharmacological options with moderate-to-high quality evidence
35246237	2022	Systematic Review + Network Meta-analysis	Molecular Autism	NMA investigating pharmacological and dietary-supplement treatments for ASD; confirmed aripiprazole efficacy for associated irritability and agitation symptoms across multiple study designs
33857522	2021	Systematic Review	Progress in Neuro-Psychopharmacology & Biological Psychiatry	Comprehensive systematic review of pediatric psychopharmacology in ASD (Part I); detailed reconstruction of the aripiprazole evidence base from open-label to Phase 3 pivotal trials
41004875	2025	RCT	Brain & Development	Head-to-head randomized controlled trial comparing risperidone vs. aripiprazole for reducing irritability severity in children with ASD; both effective, with aripiprazole offering a potentially superior metabolic safety profile
39690490	2025	Network Meta-analysis	Journal of Psychopharmacology	Updated NMA comparing pharmacotherapies for agitation in ASD and intellectual disabilities in both children and adults; aripiprazole identified as an efficacious first-line pharmacological option across age groups
36625807	2023	Narrative Review	JAMA	High-impact clinical review of ASD published in JAMA; explicitly notes aripiprazole as one of only two FDA-approved medications for ASD-associated irritability, reinforcing its guideline-level clinical positioning
20643378	2010	Narrative Review	Neurotherapeutics	Foundational early review specifically examining aripiprazole in autism spectrum disorders and fragile X syndrome; summarized preclinical rationale and early clinical evidence that preceded the FDA approval pathway
27388494	2016	Expert Review	Expert Review of Neurotherapeutics	Expert clinical review of aripiprazole for irritability and aggression in children and adolescents with ASD; affirms clinical positioning, dosing guidance (2–15 mg/day), and safety monitoring considerations post-FDA approval

Malaysia Market Information

Aripiprazole has 26 product registrations confirmed in the Malaysia NPRA database with active market status. However, detailed product-level information — including individual authorization numbers, product names, dosage forms, and approved indication texts — was not captured in the current data extraction. The table below reflects this gap.

Authorization Number	Product Name	Dosage Form	Approved Indication
Pending	(26 products registered in NPRA)	Pending	Pending — requires NPRA portal review

The key unresolved question for this repurposing evaluation is whether any of the 26 currently registered products in Malaysia carry an approved indication for irritability associated with autism spectrum disorder. If not, the existing L1 evidence base constitutes a strong foundation for an indication extension application.

Safety Considerations

Please refer to the package insert for safety information.

Package insert warnings, contraindications, and drug-drug interaction data were flagged as data gaps (DG001, DG002) in this evidence pack. Before advancing to clinical planning, these must be retrieved directly from the NPRA official website and the corresponding package insert PDFs. Key areas to review include: neuroleptic malignant syndrome risk, tardive dyskinesia, impulse control disorders (a class-effect concern with D2 partial agonists), metabolic monitoring in pediatric populations, and use in elderly patients with dementia-related psychosis.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Aripiprazole has L1-level clinical evidence — including multiple completed Phase 3 double-blind RCTs and an FDA approval — for irritability associated with autism spectrum disorder in children aged 6–17. The mechanistic rationale is well-established, the pediatric safety profile is extensively characterized, and Asia-specific data (Japan post-marketing, n=528) further supports applicability to the Malaysian clinical context. The evidence base is sufficient to proceed; the remaining work is primarily regulatory and implementation-focused.

Additional Supported Indications (Ranks 3–5): The evidence pack also identifies schizophrenia (Rank 3, L1) and bipolar disorder / manic bipolar affective disorder (Ranks 4–5, L1) as high-evidence predictions — both are globally established aripiprazole indications and likely already registered among the 26 Malaysia licenses.

To proceed, the following is needed:

Regulatory review: Retrieve and verify the approved indication text for all 26 NPRA-registered aripiprazole products — confirm whether ASD irritability is currently approved or requires an indication extension
Safety data retrieval: Download and parse package insert PDFs from the NPRA website to populate the key warnings and contraindication fields (Data Gap DG001)
MOA documentation: Query the DrugBank API to formally document the mechanism of action for regulatory submissions (Data Gap DG002)
Pediatric risk management plan: Develop monitoring protocols covering: body weight and BMI (at baseline, 4 weeks, 8 weeks, then quarterly), fasting glucose and lipid panel, extrapyramidal symptom assessment (e.g., AIMS scale), and sedation monitoring — all critical for the pediatric target population
Dose confirmation: Confirm the pediatric dose range registered or to be registered in Malaysia (globally approved range: 2–15 mg/day for ASD irritability)
Asia-Pacific comparator review: Cross-reference with Japanese and Taiwanese regulatory approvals for ASD irritability to support any Malaysia indication extension application
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.